Please login to the form below

Not currently logged in


This page shows the latest ZP2929 news and features for those working in and with pharma, biotech and healthcare.

Boehringer switches diabetes candidate in Zealand collaboration

Boehringer switches diabetes candidate in Zealand collaboration

Boehringer switches diabetes candidate in Zealand collaboration. Will swap ZP2929 for another GLP-1 receptor agonist. ... Boehringer Ingelheim has decided to drop the diabetes and obesity drug candidate ZP2929 it has spent nearly three years developing

Latest news

  • Drug delivery

    Other deals of note were Boehringer Ingelheim's (BI) agreement with Zealand Pharma for rights to its ZP2929 - GLP1 receptor agonists against type 2 diabetes and obesity, further building the ... DPP-IV inhibitors (T2D) patent estate. Divestment. 609.

  • Boehringer and Zealand focus on diabetes

    Boehringer Ingelheim will obtain global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. ... Zealand Pharma will be eligible to receive payments for ZP2929 and could receive additional

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...